[go: up one dir, main page]

UA95601C2 - 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof - Google Patents

3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof

Info

Publication number
UA95601C2
UA95601C2 UAA200708221A UAA200708221A UA95601C2 UA 95601 C2 UA95601 C2 UA 95601C2 UA A200708221 A UAA200708221 A UA A200708221A UA A200708221 A UAA200708221 A UA A200708221A UA 95601 C2 UA95601 C2 UA 95601C2
Authority
UA
Ukraine
Prior art keywords
methyl
phenylamino
carbonyl
ethyl ester
propionic acid
Prior art date
Application number
UAA200708221A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Норберт Хауэль
Петер Зигер
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Publication of UA95601C2 publication Critical patent/UA95601C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

У заявці описана нова, призначена для перорального застосування лікарська форма для діючої речовини, якою є етиловий ефір 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1-метил-1H-бензимідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти і його фармакологічно прийнятні солі.The application describes a new oral dosage form for the active substance, which is ethyl ester 3 - [(2 - {[4- (hexyloxycarbonylaminoiminomethyl) phenylamino] methyl} -1-methyl-1H-benzimidazole-5-carbonyl) pyridine -2-ylamino] propionic acid and its pharmacologically acceptable salts.

UAA200708221A 2002-03-07 2003-03-03 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof UA95601C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (en) 2002-03-07 2002-03-07 Oral pharmaceutical composition comprises the thrombin inhibitor ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate and an organic acid

Publications (1)

Publication Number Publication Date
UA95601C2 true UA95601C2 (en) 2011-08-25

Family

ID=27771070

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200708221A UA95601C2 (en) 2002-03-07 2003-03-03 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof
UA20041008096A UA81760C2 (en) 2002-03-07 2003-03-03 Normal;heading 1;heading 2;ADMINISTRATION FORM FOR THE ORAL APPLICATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO] PROPIONIC ACID ETHYL ESTER AND THE SALTS THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA20041008096A UA81760C2 (en) 2002-03-07 2003-03-03 Normal;heading 1;heading 2;ADMINISTRATION FORM FOR THE ORAL APPLICATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO] PROPIONIC ACID ETHYL ESTER AND THE SALTS THEREOF

Country Status (4)

Country Link
CN (1) CN101632668A (en)
DE (1) DE10209985A1 (en)
UA (2) UA95601C2 (en)
UY (1) UY27694A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2817000T (en) 2012-02-21 2021-11-02 Towa Pharmaceutical Europe S L Oral pharmaceutical compositions of dabigatran etexilate
CN102793699B (en) * 2012-08-06 2014-06-04 严轶东 Medicinal composition containing dabigatran etexilate
CN104414995A (en) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 Pharmaceutical composition of dabigatran etexilate mesylate
CN104825422B (en) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 Pharmaceutical composition containing dabigatran etcxilate mesylate and preparation method thereof
CN105640909B (en) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 A kind of medicinal composition containing dabigatran etexilate
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (en) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 Pharmaceutical composition of amorphous solid dispersion and preparation method thereof

Also Published As

Publication number Publication date
UY27694A1 (en) 2003-10-31
UA81760C2 (en) 2008-02-11
DE10209985A1 (en) 2003-09-25
CN101632668A (en) 2010-01-27

Similar Documents

Publication Publication Date Title
ECSP045331A (en) Presentation form for oral administration, for 3? [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-? Benzimidazole-5-carbonyl acid ethyl ester ) -pyridin-2-yl-amino] -propionic and its salts
CY1109299T1 (en) Methanesulfonic SALT 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester and USE THIS AS MEDICINAL
CY1108218T1 (en) Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1 -methyl-1 H-VENZIMIDAZOLO5-carbonyl) -pyridin-2-YL-AMINO] ETHYL PROPIONATE
NO20075862L (en) Polymorphs of ethyl 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) phenylamino] methyl} -1-methyl-1H-benzimidazole-5-carbonyl) pyridin-2-ylamino] propionate
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
ATE397605T1 (en) NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL
EA200702198A1 (en) PHARMACEUTICAL COMPOSITIONS
NZ581176A (en) Stabilized amorphous forms of imatinib mesylate the formulation is a solid dispersion
NO20043832L (en) Oral solid solution formulation of a poorly water-soluble active substance
UA95601C2 (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof
NO20050771L (en) Bicifadinformulering
NO20043633L (en) Oral dosage form for controlled drug release
FR2878443B1 (en) PHARMACEUTICAL COMPOSITION, FOR ORAL ADMINISTRATION OF HIGHLY GASTRO-LABILE ACTIVE SUBSTANCE (S) AND PREPARATION THEREOF
TH72432A (en) Tablets with 3 - [(2 - {[4- (hexyloxiocarbino-imino-methyl) -fenilaminos] - methyl) -1-methyl -1H - Benzimidazol-5-Carbonyl) - Piridin-2-Il-Amino) - Pyropionic acid Ethyl ester Or the salt of that substance
AR038306A1 (en) PHARMACEUTICAL DISPERSABLE COMPOSITION ORALALLY OF 2 - ({2-METOXI-2 - [(3-TRIFLUOROMETIL) PHENYL] ETIL} AMINO) ETIL-4- (2 - {[2- (9H-FLUOREN-9-IL) ACETIL] AMINO } ETIL) BENZOATE
NO20064112L (en) Pharmaceutical dosage forms and preparations